Giving patients treatment options
VIVUS is dedicated to meeting the needs and improving quality of life of patients with serious medical conditions and life-limiting diseases.
Our commercial products are indicated for the treatment of obese and overweight patients (Qsymia®) and exocrine pancreatic insufficiency (PANCREAZE®). According to the National Institutes of Health, overweight and obesity combined are the second leading cause of preventable death in the United States. Exocrine pancreatic insufficiency (EPI) affects many patient populations, including patients with cystic fibrosis, chronic pancreatitis, celiac disease, diabetes, both type 1 and type 2, inflammatory bowel disease and HIV infection.